Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 4, 2014, Pages 681-690

  Macedo Pérez, Eleazar Omar ^a   Morales Oyarvide, Vicente ^a   Mendoza García, Víctor Osvaldo ^a   Dorantes Gallareta, Yuzmiren ^a   Flores Estrada, Diana ^a   Arrieta, Oscar ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Docetaxel; Lung cancer; Paclitaxel; Second line

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; TAXOID;

CARCINOMA, NON-SMALL-CELL LUNG; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG SCREENING; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MEXICO; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEXICO; MIDDLE AGED; PACLITAXEL; PATIENT SELECTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TREATMENT OUTCOME;

EID: 84925546987     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2522-9     Document Type: Article

References (32)

1. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
2. INEGI 2013. Estadísticas de mortalidad en México
3. Travis WD (2011) Classification of lung cancer. Semin Roentgenol 46:178-186
4. SEER Stat Fact Sheets: Lung and Bronchus Cancer (May 1 2014): http://seer.cancer.gov/statfacts/html/lungb.html
5. Arrieta O, Guzmán-de Alba E, Alba-López LF (2013) Consenso Nacional de Diagnóstico y tratamiento de cancer pulmonar de células no pequeñas. Rev Invest Clin 65(Supl. 1):s5-s84
6. Arrieta O, Campos-Parra AD, Zuloaga Z et al (2012) Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. J Thorac Oncol 7(8):1228-1234
7. Burdett et al (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. NSCLC meta-analyses collaborative group. J Clin Oncol 26(28):4617-4625
8. Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004(59):828-836
9. Arrieta O, Núñez-Valencia C, Reynoso-Erazo L et al (2012) Health-related quality of life in patients with lung cancer: validation of the mexican-spanish version and association with prognosis of the EORTC QLQ-LC113 questionnaire. Lung Cancer 77(1):205-211
10. Kelly K, Crowley J, Bunn PA et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial. J Clin Oncol 19:3210-3218
11. Scagliotti GV, De Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20(21):4285-4291
12. Schiller JH, Arrington DH, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98
13. Scagliotti GV, Parikh P, Von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551
14. Tassinari D, Scarpi E, Sartori S et al (2009) Second-line treatments in non-small cell lung cancer. A systematic review of literatura and metaanalysis of randomized clinical trials. Chest 135:1596-1609
15. Sculier JP, Moro-Sibilot D (2009) First and second-line therapy for advanced non-small cell lung cancer. Eur Respir J 33:915-930
16. NCCN guidelines Version 3, 2014: non-small cell lung cancer
17. Shepherd FA, Dancey J, Ramlau R et al (2000) PROSPECTIVE randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103
18. Gligorov J, Lotz JP (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2):3-8
19. Fossella FV, Lee JS, Shin DM et al (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651
20. Gandara DR, Vokes E, Green M et al (2000) Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 18:131-135
21. Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362
22. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597
23. Cortes JE, Pazdur R (1995) Docetaxel, article review. J Clin Oncol 13:2643-2655
24. Lin S, Ojima I (2000) Recent strategies in the development of taxane anticancer drugs. Expert Opin Ther Pat 10(6):869-889
25. Sawaki M, Ito Y, Hashimoto D et al (2004) Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 90:36-39
26. Valero V, Jones SE, Von Hoff DD et al (1998) A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 16(10):3362-3368
27. Verschraegen CF, Sittisomwong T, Kudelka AP et al (2000) Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. J Clin Oncol 18(14):2733-2739
28. Gandara DR, Edelman MJ, Lau D et al (2000) Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer. Semin Oncol 26(3 Suppl 10):3-7
29. Arrieta O, Cardona AF, Bramuglia F et al (2011) Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 6(11):1955-1959. doi: 10.1097/JTO.0b013e31822f655f
30. Miura S, Murakami H, Tamiya A et al (2011) Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors. Oncol Lett 2:1059-1064
31. Douillard JY, Shepherd FA, Hirsh V et al (2010) molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III interest trial. J Clin Oncol 28(5):744-752
32. Arrieta O, Villarreal-Garza C, Pachuca D et al (2011) High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Med Oncol 28(1):300-306. doi: 10.1007/s12032-009-9401-y